AAAAAA

   
Results: 1-25 | 26-43
Results: 1-25/43
ALLOGENEIC CELL-MEDIATED IMMUNOTHERAPY FOR BREAST-CANCER AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION - A CLINICAL PILOT-STUDY
Authors: OR R ACKERSTEIN A NAGLER A KAPELUSHNIK J NAPARSTEK E SAMUEL S AMAR A BRUATBAR C SLAVIN S
Citation: R. Or et al., ALLOGENEIC CELL-MEDIATED IMMUNOTHERAPY FOR BREAST-CANCER AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION - A CLINICAL PILOT-STUDY, Cytokines cellular & molecular therapy, 4(1), 1998, pp. 1-6
ALLOGENEIC CELL-MEDIATED AND CYTOKINE-ACTIVATED IMMUNOTHERAPY FOR MALIGNANT-LYMPHOMA AT THE STAGE OF MINIMAL RESIDUAL DISEASE AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION
Authors: OR R ACKERSTEIN A NAGLER A AMAR A NAPARSTEK E VARADI G KAPELUSHNIK J SAMUEL S PUGATSCH T BRAUTBAR C SLAVIN S
Citation: R. Or et al., ALLOGENEIC CELL-MEDIATED AND CYTOKINE-ACTIVATED IMMUNOTHERAPY FOR MALIGNANT-LYMPHOMA AT THE STAGE OF MINIMAL RESIDUAL DISEASE AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION, Journal of immunotherapy, 21(6), 1998, pp. 447-453
POST TRANSPLANT IMMUNOTHERAPY FOR PREVENTION OF RELAPSE AFTER AUTOLOGOUS BMT FOR ACUTE-LEUKEMIA
Authors: NAPARSTEK E NAGLER A OR R VARADI G BENYOSEF R ACKERSTEIN A SLAVIN S
Citation: E. Naparstek et al., POST TRANSPLANT IMMUNOTHERAPY FOR PREVENTION OF RELAPSE AFTER AUTOLOGOUS BMT FOR ACUTE-LEUKEMIA, Experimental hematology, 26(8), 1998, pp. 353-353
ADOPTIVE CELL-MEDIATED IMMUNOTHERAPY WITH INTERLEUKIN-2 (IL-2) FOR RELAPSING LYMPHOBLASTIC CRISIS FOLLOWING MISMATCHED UNRELATED BONE-MARROW TRANSPLANTATION IN A CHRONIC MYELOGENOUS LEUKEMIA PATIENT
Authors: VARADI G ACKERSTEIN A BENNERIAH S NAGLER A
Citation: G. Varadi et al., ADOPTIVE CELL-MEDIATED IMMUNOTHERAPY WITH INTERLEUKIN-2 (IL-2) FOR RELAPSING LYMPHOBLASTIC CRISIS FOLLOWING MISMATCHED UNRELATED BONE-MARROW TRANSPLANTATION IN A CHRONIC MYELOGENOUS LEUKEMIA PATIENT, Bone marrow transplantation, 21(1), 1998, pp. 93-96
ALLOGENEIC BLOOD STEM-CELL TRANSPLANTATION FOLLOWING NON-MYELOABLATIVE CONDITIONING FOR THE TREATMENT OF MALIGNANT AND NONMALIGNANT DISEASES
Authors: SLAVIN S NAGLER A NAPARSTEK E ACKERSTEIN A KAPELUSHNIK Y VARADI G ALLAYAN H KIRSCHBAUM M BENYOSEF R SAMUEL S
Citation: S. Slavin et al., ALLOGENEIC BLOOD STEM-CELL TRANSPLANTATION FOLLOWING NON-MYELOABLATIVE CONDITIONING FOR THE TREATMENT OF MALIGNANT AND NONMALIGNANT DISEASES, Bone marrow transplantation, 21, 1998, pp. 225-225
LONG-TERM IMMUNOTHERAPY WITH INTERFERON-ALPHA (IFN-ALPHA)FOR MULTIPLE-MYELOMA PATIENTS FOLLOWING AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT)
Authors: ACKERSTEIN A NAGLER A NAPARSTEK E KAPELUSHNIK J VARADI G SLAVIN S OR R
Citation: A. Ackerstein et al., LONG-TERM IMMUNOTHERAPY WITH INTERFERON-ALPHA (IFN-ALPHA)FOR MULTIPLE-MYELOMA PATIENTS FOLLOWING AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT), Bone marrow transplantation, 21, 1998, pp. 708-708
NONMYELOABLATIVE STEM-CELL TRANSPLANTATION AND CELL THERAPY AS AN ALTERNATIVE TO CONVENTIONAL BONE-MARROW TRANSPLANTATION WITH LETHAL CYTOREDUCTION FOR THE TREATMENT OF MALIGNANT AND NONMALIGNANT HEMATOLOGIC DISEASES
Authors: SLAVIN S NAGLER A NAPARSTEK E KAPELUSHNIK Y AKER M CIVIDALLI G VARADI G KIRSCHBAUM M ACKERSTEIN A SAMUEL S AMAR A BRAUTBAR C BENTAL O ELDOR A OR R
Citation: S. Slavin et al., NONMYELOABLATIVE STEM-CELL TRANSPLANTATION AND CELL THERAPY AS AN ALTERNATIVE TO CONVENTIONAL BONE-MARROW TRANSPLANTATION WITH LETHAL CYTOREDUCTION FOR THE TREATMENT OF MALIGNANT AND NONMALIGNANT HEMATOLOGIC DISEASES, Blood, 91(3), 1998, pp. 756-763
CONTINUOUS INTERLEUKIN-2 INFUSION COMBINED WITH CYCLOPHOSPHAMIDE-BASED COMBINATION CHEMOTHERAPY IN THE TREATMENT OF HEMATO-ONCOLOGICAL MALIGNANCIES - RESULTS OF A PHASE I-II STUDY
Authors: NAGLER A ACKERSTEIN A BENSHAHAR M OR R NAPARSTEK E BENYOSEF R SLAVIN S
Citation: A. Nagler et al., CONTINUOUS INTERLEUKIN-2 INFUSION COMBINED WITH CYCLOPHOSPHAMIDE-BASED COMBINATION CHEMOTHERAPY IN THE TREATMENT OF HEMATO-ONCOLOGICAL MALIGNANCIES - RESULTS OF A PHASE I-II STUDY, Acta haematologica, 100(2), 1998, pp. 63-68
ACTIVATED LONG-TERM PERIPHERAL-BLOOD CULTURES AS PREPARATION FOR ADOPTIVE ALLOREACTIVE CELL THERAPY IN CANCER-PATIENTS
Authors: MORECKI S GELFAND Y LEVI S NAGLER A CONDIOTTI R NABET C ACKERSTEIN A SLAVIN S
Citation: S. Morecki et al., ACTIVATED LONG-TERM PERIPHERAL-BLOOD CULTURES AS PREPARATION FOR ADOPTIVE ALLOREACTIVE CELL THERAPY IN CANCER-PATIENTS, Journal of hematotherapy, 6(2), 1997, pp. 115-124
NON MYELOABLATIVE CONDITIONING IN PREPARATION FOR ALLOGENEIC STEM-CELL TRANSPLANTATION - THE FUTURE TREATMENT OF CHOICE OF HEMATOLOGIC MALIGNANCIES AND GENETIC-DISEASES
Authors: SLAVIN S NAGLER A NAPARSTEK E KAPELUSHNIK J VARADI G KIRSCHBAUM M HUSSIEN A ACKERSTEIN A OR R
Citation: S. Slavin et al., NON MYELOABLATIVE CONDITIONING IN PREPARATION FOR ALLOGENEIC STEM-CELL TRANSPLANTATION - THE FUTURE TREATMENT OF CHOICE OF HEMATOLOGIC MALIGNANCIES AND GENETIC-DISEASES, Experimental hematology, 25(8), 1997, pp. 204-204
MAJOR SALIVARY-GLAND DYSFUNCTION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES RECEIVING INTERLEUKIN-2-BASED IMMUNOTHERAPY POST-AUTOLOGOUS BLOOD STEM-CELL TRANSPLANTATION (ABSCT)
Authors: NAGLER A NAGLER R ACKERSTEIN A LEVI S MARMARY Y
Citation: A. Nagler et al., MAJOR SALIVARY-GLAND DYSFUNCTION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES RECEIVING INTERLEUKIN-2-BASED IMMUNOTHERAPY POST-AUTOLOGOUS BLOOD STEM-CELL TRANSPLANTATION (ABSCT), Bone marrow transplantation, 20(7), 1997, pp. 575-580
INVASIVE FUNGAL-INFECTIONS IN LYMPHOMA PATIENTS RECEIVING IMMUNOTHERAPY FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT)
Authors: TOREN A OR R ACKERSTEIN A NAGLER A
Citation: A. Toren et al., INVASIVE FUNGAL-INFECTIONS IN LYMPHOMA PATIENTS RECEIVING IMMUNOTHERAPY FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT), Bone marrow transplantation, 20(1), 1997, pp. 67-69
IMPLICATIONS OF DONOR LYMPHOCYTE INFUSION (DLI) ON ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) TOLERANCE IN PATIENTS IN RELAPSE VS. REMISSION POST MATCHED ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT)
Authors: NAGLER A ACKERSTEIN A NAPARSTEK E OR R KAPELUSHNIK J SAMUEL S SLAVIN S
Citation: A. Nagler et al., IMPLICATIONS OF DONOR LYMPHOCYTE INFUSION (DLI) ON ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) TOLERANCE IN PATIENTS IN RELAPSE VS. REMISSION POST MATCHED ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT), Blood, 90(10), 1997, pp. 4470-4470
PULSE THERAPY WITH INTERLEUKIN-2 (RIL-2) FOLLOWED BY INTERFERON-ALPHA(IFN-ALPHA) MAINTENANCE IMMUNOTHERAPY FOR MALIGNANT-LYMPHOMA (ML) PATIENTS (PTS) POST AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION(ABSCT)
Authors: NAGLER A ACKERSTEIN A OR R NAPARSTEK E SLAVIN S
Citation: A. Nagler et al., PULSE THERAPY WITH INTERLEUKIN-2 (RIL-2) FOLLOWED BY INTERFERON-ALPHA(IFN-ALPHA) MAINTENANCE IMMUNOTHERAPY FOR MALIGNANT-LYMPHOMA (ML) PATIENTS (PTS) POST AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION(ABSCT), Blood, 90(10), 1997, pp. 1700-1700
SUCCESSFUL REPLACEMENT OF CONVENTIONAL ALLOGENEIC BONE-MARROW OR BLOOD STEM-CELL TRANSPLANTATION WITH TOLERATED NON-MYELOABLATIVE CONDITIONING FOR THE TREATMENT OF MALIGNANT AND NONMALIGNANT DISEASES
Authors: SLAVIN S NAGLER A NAPARSTEK E ACKERSTEIN A KAPELUSHNIK Y VARADI G KIRSCHBAUM M BENYOSEF R SAMUEL S OR R
Citation: S. Slavin et al., SUCCESSFUL REPLACEMENT OF CONVENTIONAL ALLOGENEIC BONE-MARROW OR BLOOD STEM-CELL TRANSPLANTATION WITH TOLERATED NON-MYELOABLATIVE CONDITIONING FOR THE TREATMENT OF MALIGNANT AND NONMALIGNANT DISEASES, Blood, 90(10), 1997, pp. 2378-2378
IMMUNOTHERAPY WITH RECOMBINANT HUMAN INTERLEUKIN-2 AND RECOMBINANT INTERFERON-ALPHA IN LYMPHOMA PATIENTS POSTAUTOLOGOUS MARROW OR STEM-CELLTRANSPLANTATION
Authors: NAGLER A ACKERSTEIN A OR R NAPARSTEK E SLAVIN S
Citation: A. Nagler et al., IMMUNOTHERAPY WITH RECOMBINANT HUMAN INTERLEUKIN-2 AND RECOMBINANT INTERFERON-ALPHA IN LYMPHOMA PATIENTS POSTAUTOLOGOUS MARROW OR STEM-CELLTRANSPLANTATION, Blood, 89(11), 1997, pp. 3951-3959
THE EFFECT OF POST TRANSPLANT ADMINISTRATION OF DONOR LYMPHOCYTES ON PREVENTION OF LEUKEMIC RELAPSE IN T-CELL DEPLETED ALLOGENEIC BMT
Authors: NAPARSTEK E OR R NAGLER A KAPELUSHNIK J ACKERSTEIN A SAMUEL S AKER M CIVIDALLI G SLAVIN S
Citation: E. Naparstek et al., THE EFFECT OF POST TRANSPLANT ADMINISTRATION OF DONOR LYMPHOCYTES ON PREVENTION OF LEUKEMIC RELAPSE IN T-CELL DEPLETED ALLOGENEIC BMT, Experimental hematology, 24(9), 1996, pp. 613-613
ACTIVATED ALLOGENEIC CELL THERAPY (ALLO-ACT) FOR RELAPSED CHRONIC MYELOGENOUS LEUKEMIA (CML) REFRACTORY TO BUFFY COAT TRANSFUSIONS POST-ALLOGENEIC BONE-MARROW TRANSPLANTATION
Authors: KAPELUSHNIK J NAGLER A OR R NAPARSTEK E ACKERSTEIN A SAMUEL S MORECKI S NABET C SLAVIN S
Citation: J. Kapelushnik et al., ACTIVATED ALLOGENEIC CELL THERAPY (ALLO-ACT) FOR RELAPSED CHRONIC MYELOGENOUS LEUKEMIA (CML) REFRACTORY TO BUFFY COAT TRANSFUSIONS POST-ALLOGENEIC BONE-MARROW TRANSPLANTATION, Bone marrow transplantation, 18(6), 1996, pp. 1153-1156
SOLUBLE IL-6 RECEPTORS (SIL-6R) IN HEMATOLOGICAL PATIENTS RECEIVING IMMUNOTHERAPY WITH IL-2 IFN-ALPHA OR DONOR LYMPHOCYTES FOLLOWING BONE-MARROW TRANSPLANTATION/
Authors: TOREN A NOVICK D ACKERSTEIN A OR R SLAVIN S NAGLER A
Citation: A. Toren et al., SOLUBLE IL-6 RECEPTORS (SIL-6R) IN HEMATOLOGICAL PATIENTS RECEIVING IMMUNOTHERAPY WITH IL-2 IFN-ALPHA OR DONOR LYMPHOCYTES FOLLOWING BONE-MARROW TRANSPLANTATION/, Bone marrow transplantation, 18(4), 1996, pp. 721-724
ORAL TUBERCULOSIS FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR HODGKINS-DISEASE WITH INTERLEUKIN-2 AND ALPHA-INTERFERON IMMUNOTHERAPY
Authors: TOREN A ACKERSTEIN A GAZIT D OR R RAVEH D KUPOLOVICZ U ENGELHARD D NAGLER A
Citation: A. Toren et al., ORAL TUBERCULOSIS FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR HODGKINS-DISEASE WITH INTERLEUKIN-2 AND ALPHA-INTERFERON IMMUNOTHERAPY, Bone marrow transplantation, 18(1), 1996, pp. 209-210
SOLUBLE INTERLEUKIN-6 RECEPTORS IN HEMATOLOGY PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION
Authors: TOREN A NOVICK D OR R ACKERSTEIN A SLAVIN S NAGLER A
Citation: A. Toren et al., SOLUBLE INTERLEUKIN-6 RECEPTORS IN HEMATOLOGY PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION, Transplantation, 62(1), 1996, pp. 138-142
SUCCESSFUL CONTROL OF RELAPSED LEUKEMIA RESISTANT TO ALLOGENEIC BONE-MARROW TRANSPLANTATION AND DONOR LYMPHOCYTE INFUSION WITH RIL-2-ACTIVATED DONOR-DERIVED BLOOD-LYMPHOCYTES
Authors: SLAVIN S NAPARSTEK E NAGLER A ACKERSTEIN A KAPELUSHNIK Y VARADI G KIRSCHBAUM M BENYOSEF R SAMUEL S OR R
Citation: S. Slavin et al., SUCCESSFUL CONTROL OF RELAPSED LEUKEMIA RESISTANT TO ALLOGENEIC BONE-MARROW TRANSPLANTATION AND DONOR LYMPHOCYTE INFUSION WITH RIL-2-ACTIVATED DONOR-DERIVED BLOOD-LYMPHOCYTES, Blood, 88(10), 1996, pp. 1023-1023
ALLOGENEIC CELL THERAPY (ALLOCT) FOR PREVENTION OF RELAPSE IN HIGH-RISK ACUTE-LEUKEMIA FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION - CONTROL OF GVHD BY GRADED INCREMENTS OF DONOR LYMPHOCYTE INFUSION
Authors: SLAVIN S OR R NAGLER A ACKERSTEIN A KAPELUSHNIK Y VARADI G KIRSCHBAUM M BENYOSEF R SAMUEL S NAPARSTEK E
Citation: S. Slavin et al., ALLOGENEIC CELL THERAPY (ALLOCT) FOR PREVENTION OF RELAPSE IN HIGH-RISK ACUTE-LEUKEMIA FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION - CONTROL OF GVHD BY GRADED INCREMENTS OF DONOR LYMPHOCYTE INFUSION, Blood, 88(10), 1996, pp. 1661-1661
IMMUNOTHERAPY OF LEUKEMIA IN CONJUNCTION WITH NON-MYELOABLATIVE CONDITIONING - ENGRAFTMENT OF BLOOD STEM-CELLS AND ERADICATION OF HOST LEUKEMIA WITH NON-MYELOABLATIVE CONDITIONING BASED ON FLUDARABINE AND ANTI-THYMOCYTE GLOBULIN (ATG)
Authors: SLAVIN S NAGLER A NAPARSTEK E ACKERSTEIN A KAPELUSHNIK Y VARADI G KIRSCHBAUM M BENYOSEF R SAMUEL S OR R
Citation: S. Slavin et al., IMMUNOTHERAPY OF LEUKEMIA IN CONJUNCTION WITH NON-MYELOABLATIVE CONDITIONING - ENGRAFTMENT OF BLOOD STEM-CELLS AND ERADICATION OF HOST LEUKEMIA WITH NON-MYELOABLATIVE CONDITIONING BASED ON FLUDARABINE AND ANTI-THYMOCYTE GLOBULIN (ATG), Blood, 88(10), 1996, pp. 2443-2443
ALLOGENEIC CELL THERAPY - THE TREATMENT OF CHOICE FOR ALL HEMATOLOGICMALIGNANCIES RELAPSING POST BMT
Authors: SLAVIN S NAPARSTEK E NAGLER A KAPELUSHNIK Y ACKERSTEIN A OR R
Citation: S. Slavin et al., ALLOGENEIC CELL THERAPY - THE TREATMENT OF CHOICE FOR ALL HEMATOLOGICMALIGNANCIES RELAPSING POST BMT, Blood, 87(9), 1996, pp. 4011-4012
Risultati: 1-25 | 26-43